Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) SVP Joseph R. Young sold 5,714 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the transaction, the senior vice president now directly owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Vera Therapeutics Price Performance
Shares of VERA opened at $47.97 on Friday. Vera Therapeutics, Inc. has a twelve month low of $6.05 and a twelve month high of $50.78. The firm’s fifty day simple moving average is $43.39 and its 200-day simple moving average is $25.05. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -20.95 and a beta of 1.05. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49.
Institutional Investors Weigh In On Vera Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Vera Therapeutics by 39.7% in the 1st quarter. FMR LLC now owns 5,796,259 shares of the company’s stock valued at $44,979,000 after purchasing an additional 1,647,613 shares in the last quarter. Kynam Capital Management LP raised its holdings in shares of Vera Therapeutics by 23.5% in the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock valued at $56,142,000 after purchasing an additional 694,286 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Vera Therapeutics by 53.9% in the 2nd quarter. BlackRock Inc. now owns 2,170,134 shares of the company’s stock valued at $34,831,000 after purchasing an additional 759,864 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Vera Therapeutics by 1.6% in the 2nd quarter. Citadel Advisors LLC now owns 2,122,851 shares of the company’s stock valued at $28,892,000 after purchasing an additional 33,331 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Vera Therapeutics by 3.8% in the 4th quarter. Vanguard Group Inc. now owns 1,633,608 shares of the company’s stock valued at $25,125,000 after purchasing an additional 59,218 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
View Our Latest Research Report on VERA
About Vera Therapeutics
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
See Also
- Five stocks we like better than Vera Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- 5 Trends You Need to Know This Quarter
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 4/8 – 4/12
- What is the Euro STOXX 50 Index?
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.